Signaling in Human Mammary Epithelial Cells
Annette Säfholm,
Christian Kamp Nielsen,
Tommy Andersson, and
Karin Leandersson*
Experimental Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, Malmö, Sweden
Received 9 December 2005/ Returned for modification 5 January 2006/ Accepted 17 May 2006
| ABSTRACT |
|---|
|
|
|---|
, even upon treatment with ionomycin, which was blocked upon inhibition of the Wnt-5a/Yes/Cdc42 signaling pathway. Our results explain why Wnt-5a/Ca2+-induced NFAT activity is hard to detect and suggest a novel mechanism by which Wnt-5a can suppress tumor-specific, agonist-induced NFAT activity and thus the metastatic behavior of breast cancer cells. | INTRODUCTION |
|---|
|
|
|---|
Wnt signaling is complex since the signals are transduced through several different pathways, depending on the Wnt type and the tissue analyzed (44, 47, 63). The signal pathway that has been best characterized to date is the canonical (ß-catenin) Wnt pathway, which is highly conserved among species and is responsible for many important cellular processes (44, 47, 56, 63). Several noncanonical pathways (Wnt-5a, Wnt-11, and XWnt-4) have also been described, including the Wnt/Ca2+ signaling pathway, and the relationship between these pathways has been thoroughly discussed in a recent review (63). Briefly, signaling by Wnt-5a can trigger the noncanonical Wnt/Ca2+ pathway, leading to an increase in intracellular Ca2+ and activation of calcium-sensitive enzymes, such as calcineurin, and Ca2+/calmodulin-regulated kinase II (31, 57). Stimulation of calcium-sensitive enzymes such as these often leads to the activation of NFAT (for nuclear factor of activated T cells) transcription factor proteins in many cell types (5, 50), but it has been unclear whether the same applies to signaling by Wnt-5a and other Wnts (43, 53, 61). In addition, other noncanonical Wnt pathways have been described and shown to control planar cell polarity in Drosophila and convergent extension movements in vertebrates, and several investigators have reported that the Jun N-terminal kinase (JNK [6]) and small Rho-GTPases (RhoA, Rac1, or Cdc42 [35, 44]) are involved in these cascades (63).
Wnt-5a has been proposed to exert its effects via the Wnt/Ca2+ pathway, based on results obtained in both Xenopus (53) and mammalian cells; the latter is exemplified by receptor-blocking experiments in malignant melanomas where Wnt-5a can signal through frizzled receptor (Fz) 5 and thereby activate protein kinase C (PKC) (31, 65). There are conflicting results as to whether such Wnt/Ca2+-induced signaling leads to the activation of NFAT-dependent transcription or not (53, 61). Importantly, Wnt-5a has also been shown to activate other noncanonical pathways (47, 63, 68). Apparently, a single Wnt ligand can use divergent pathways in different cell types.
The transcription factor NFAT is expressed as five isoforms (NFAT1 to NFAT5; nomenclature proposed by Hoey et al. [22]; for a review, see reference 50) in various tissues. NFAT1 and NFAT5 have recently been implicated in invasive breast cancer and metastasis (23, 69). Activation of NFAT1 to NFAT4 comprises three steps: dephosphorylation, nuclear translocation, and an increase in affinity for DNA. The deactivation is regulated by active mechanisms of rephosphorylation and nuclear export. NFATs are phosphorylated on several serine residues, and the phosphorylation of distinct serines is probably brought about by different kinases, such as JNK, glycogen synthase kinase 3ß (GSK-3ß), casein kinase 1 (CK1
and CK1
), and p21-activated kinase 1 (Pak1) (3, 4, 45, 67, 70).
We have previously shown that expression of the Wnt-5a protein is a predictor of longer disease-free survival in human breast cancer (25). Since both the loss of Wnt-5a (25) and induced NFAT activity (23, 69) have been implicated in invasive breast cancer, we investigated how Wnt-5a signaling might be associated with NFAT activity in breast epithelial cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Chemicals and reagents.
Anti-CK1
and anti-NFAT1 antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), and antibodies to phosphorylated JNK, total JNK, phosphorylated GSK-3ß, phosphorylated (Ser 144) Pak1, and total Pak1 came from Cell Signaling (Beverly, MA). We purchased anti-total Yes and GSK-3ß from BD Transduction Laboratories (Franklin Lakes, NJ), JNK inhibitor II from Calbiochem (La Jolla, CA), Fura-2 AM from Molecular Probes (Eugene, OR), anti-Cdc42 from Signal Transduction (Lexington, KY), and the G410 anti-phosphotyrosine antibody from Upstate Biotech, Inc. (Lake Placid, NY). The polyclonal rabbit Wnt-5a antibody directed against the C terminus of human Wnt-5a was developed in our laboratory (25). The Src-family kinase inhibitor 4-amino-5-(4-methyl-phenyl)-7-(t-butyl) pyrozolo-D-3,4-pyrimidine (PP1) was from Alexis Biochemicals (San Diego, CA), the casein kinase 1 inhibitor IC261 was from Santa Cruz Biotechnology (Santa Cruz, CA), and the PKC inhibitor bisindolylmaleimide-I (GFX), the Src-family kinase specific inhibitor Su6656, ionomycin, cyclosporine (CS), phorbol myristate acetate (PMA), and cytochalasin D were from Sigma-Aldrich (St. Louis, MO). Recombinant mouse Wnt-5a (0.4 to 1.6 µg/ml) and Wnt-3a (100 ng/ml) was from R&D Systems (Rochester, MN). We have experienced variations in efficiency of recombinant Wnt-5a, and therefore the recombinant Wnt-5a concentrations used in the present study vary between 0.4 and 1.6 µg/ml. All other laboratory reagents were obtained from Sigma Chemicals (St. Louis, MO).
Western blotting and immunoprecipitation.
Adherent cells grown to subconfluency on tissue culture-coated plates or cells plated on collagen-coated plates were lysed in hot Laemmli buffer and dithiothreitol (DTT) for whole-cell lysates. For immunoprecipitations, the cells were serum and/or insulin starved overnight; left unstimulated or stimulated as described; and lysed in 1 ml of lysis buffer containing 100 mM Tris-HCl (pH 7.5), 1% Triton X-100, 5 mM EDTA, 5 mM EGTA, 50 mM NaCl, 4 mM Na3VO4, 20 µg of aprotinin/ml, 1 µg of leupeptin/ml, 2.5 mM benzamidine, and 2 mM Pefabloc (Roche). The supernatants were collected, and protein concentrations were measured. The lysates were precleared with protein-A Sepharose or protein-G Agarose (CK1
), and immunoprecipitations were performed with preconjugated beads, except for Yes immunoprecipitations that required preincubation with the antibody. The beads were washed five times in ice-cold wash buffer (50 mM HEPES [pH 7.4], 1% Triton X-100, 0.1% sodium dodecyl sulfate [SDS], 150 mM NaCl, 2 mM Na3VO4) and were boiled immediately in Laemmli buffer with DTT. The membranes were probed with antibodies to Wnt-5a (1:2,000), phospho-JNK (1:1,000), JNK (1:1,000), Cdc42 (1:1,000), phosphotyrosine (1:5,000), NFAT1 (1:200), Ack1 (1:1,000), phospho-GSK-3ß (1:500), GSK-3ß (1:1,000), phospho-Pak1 (1:1,000), Pak1 (1:1,000), or DDR1 (1:10,000), CK1
(1:500), and Yes (1:2,000) for 1 h at room temperature. The separated protein bands were visualized by incubating the membranes with horseradish peroxidase-conjugated secondary antibodies and with enhanced chemiluminescence. The chemicals used in the experiments were added at the times and concentrations indicated. For analysis of Wnt-5a protein levels in conditioned media, 15 ml of cell culture media from confluent Wnt-5ahigh and Wnt-5alow cells were centrifuged in Amicon Ultra Centrifugation Filter Devices (30,000 molecular weight cutoff; Millipore, Bedford, MA).
GST pull-down assay. The cDNA of the Cdc42-binding domain from PAK1B (PAKcrib; amino acids 56 to 267) was cloned into bacterial expression vector pGEX-2T (10) and was expressed in Escherichia coli as a fusion protein with glutathione S-transferase (GST). For GST pull-down assays, the cells were lysed in a buffer composed of 50 mM Tris (pH 7.5), 1% Triton X-100, 100 mM NaCl, 10 mM MgCl2, 5% glycerol, 2 mM Na3VO4, 20 µg of aprotinin/ml, 1 µg of leupeptin/ml, 2.5 mM benzamidine, and 2 mM pefabloc. The lysates were centrifuged for 30 s at 15,000 x g, the Triton X-100-soluble fractions were recovered, and protein concentrations were determined. The bacterial lysate containing the GST-PAK-crib fusion protein was added to the samples together with GST beads. After 1 h, the beads were collected and washed three times in 25 mM Tris (pH 7.5)-1% Triton X-100-100 mM NaCl-30 mM MgCl2-1 mM DTT-1 mM Na3VO4. The beads were then resuspended in Laemmli buffer and boiled for 5 min under reducing conditions. The precipitated proteins were separated by electrophoresis, and the membranes were probed with antibodies against Rac1 or Cdc42. The blots were reprobed with anti-GST antibodies, and blots examining the total Cdc42 or Rac1 levels were run in parallel.
Transient transfections and luciferase assays. Wnt-5ahigh or Wnt-5alow cells were transfected with oligofectamine reagent (Invitrogen) according to the manufacturer's instructions. Each transfection was performed with 106 cells, 1 µg of reporter gene construct, and 0.2 µg of cytomegalovirus (CMV)-controlled Renilla reporter gene. The reporter genes used were human NFAT-pGL2 (AP1 independent) and a TATA-box cloned into pGL3 as a basic transcriptional background control (TATA-pGL3) or the TOP/FOPflash vectors. In cotransfection experiments, we used 1 µg of reporter gene construct, 1 µg of expression plasmid (dominant-negative Cdc42, Rac1 or wt hLRP6), and 0.2 µg of CMV-controlled Renilla. After 36 h, protein extracts were prepared, and luciferase assays were performed with a dual-luciferase reporter assay system (Promega). The obtained luciferase activity was normalized against the activity of the cotransfected Renilla reporter gene and the TATA background in the two different cell clones. Transfections for the JNK activation experiments were performed for 36 h, using 5 x 106 cells and 3 µg of dominant-negative Cdc42, Rac1, or empty vector. The expression levels were analyzed with anti-Myc antibodies. With the exception of cytochalasin D, treatment with all chemicals used in the transfection experiments (PP1, CS, GFX, BAPTA, PMA, and JNKinh) occurred for 36 h at the concentrations indicated in the figure legends. Cytochalasin D was used as described elsewhere (51). For the invasion assays SYF cells were transfected for 18 h using Oligofectamine (Invitrogen), Optimem (Gibco), and a control vector (empty vector) or the NFAT blocking vector VIVIT-green fluorescent protein (GFP) (NFAT regulatory domain originally produced by A. Rao [2] and purchased from Addgene; plasmid 11106). The cells were subsequently cultured in normal medium for 48 h and then harvested for invasion assays.
Immunofluorescence. Wnt-5alow cells were seeded on glass coverslips and grown overnight to allow them to adhere. Thereafter, the Wnt-5alow cells were treated with recombinant mouse Wnt-5a (0.8 µg/ml; R&D Systems) for 1 h or were left untreated. Thereafter, the cells were washed with phosphate-buffered saline (PBS), fixed in freshly prepared 4% paraformaldehyde for 15 min, permeabilized in PBS-0.5% Triton X-100 for 15 min, and then blocked in 3% bovine serum albumin-PBS for 1 h at room temperature. Staining was performed with a mouse monoclonal anti-NFAT1 antibody (Affinity Bio Reagents) at 1:100 or isotype control antibodies in 1% bovine serum albumin-PBS for 1 h at room temperature, after which the cells were washed six times with PBS and then incubated with secondary anti-mouse Alexa 488 (1:500) antibodies. Next, the coverslips were washed six times in PBS, mounted in fluorescent mounting medium (Dako A/S), and examined and photographed in a Nikon Eclipse 800 microscope using a x60 objective lens. Images were recorded with a scientific-grade, charge-coupled device camera (Hamamatsu, Japan) and were analyzed with HazeBuster deconvolution software (VayTek, Inc., Fairland, CT).
Calcium imaging. HB2 or SYF cells were incubated with 4 µM fura-2/AM for 30 min, after which they were washed and placed in a chamber containing a physiologically balanced calcium medium (136 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.1 mM CaCl2, 1.2 mM KH2PO4, 5 mM NaHCO3, 5.5 mM glucose, 20 mM HEPES [pH 7.4]) at 37°C. The chamber was placed in a Nikon Diaphot microscope equipped with a Photon Technology International imaging system, and the cells were allowed to rest for 10 min. Fluorescent signals of cells were recorded before and after stimulation with Wnt-5a (0.8 µg/ml) or Wnt-3a (100 ng/ml) using excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm. At least 40 ratios were recorded per minute. For each experiment, the fluorescence intensity from all cells in the field of vision was monitored, after which the calcium response of at least 10 single cells was calculated as the change in fluorescence intensity ratio (340/380 nm) using PTI image master software. Each single trace shown is a representative of at least three independent experiments. The Wnt-5a-induced calcium response was detected in more than 95% of the cells that were imaged.
Matrigel invasion assays. Invasion assays were carried out using Matrigel invasion chambers (BD) with 8.0-µm-pore-size pore membranes in 24-well plates. HB2 Wnt-5alow and SYF cells were harvested, washed, and resuspended at a concentration of 105 cells per ml in serum-free culture media. Serum-containing medium (10% fetal calf serum [FCS]) was added to the lower well, and 0.5 ml (5 x 104 cells) of the cell suspension, containing recombinant Wnt-5a (0.8 µg/ml) where indicated, was added to the invasion chamber, and the cells were allowed to invade for 72 h (HB2 Wnt-5alow cells) or 36 h (SYF cells). Cells that had invaded through the Matrigel were fixed (4% paraformaldehyde), stained with crystal violet (Sigma Aldrich), and counted. The lower wells were always checked for cells to ensure that the experiments were stopped at the appropriate time for each cell type. SYF-cell transfection procedures were as described above, and the transfection efficiency (ca. 50%) was evaluated by using fluorescence microscopy (GFP).
| RESULTS |
|---|
|
|
|---|
|
|
|
Wnt-5a-induced activation of Yes and Cdc42 counteracts its Ca2+-induced activation of NFAT. To evaluate which Src-kinase is activated by Wnt-5a, we performed Wnt-5a-induced tyrosine phosphorylation studies of the Src-kinases Src, Fyn, and Yes. Neither Src nor Fyn was activated by recombinant Wnt-5a as measured by immunoprecipitation and immunoblotting for phosphotyrosine or by phospho Src-enzyme-linked immunosorbent assays (data not shown). However, the Src kinase Yes was phosphorylated by recombinant Wnt-5a already after 5 s and peaked within the first minute (Fig. 4A).
|
|
Cytoplasmic localization of NFAT1 is regulated by Wnt-5a. As previously mentioned NFAT activity is mainly regulated by phosphorylation of serine residues, thus leading to its cytoplasmic sequestration. Whether this process is an active nuclear export mechanism or an active inhibition of nuclear import is not fully understood (50). However, one way of measuring whether Wnt-5a indeed inhibits NFAT activity is to investigate the effects of Wnt-5a on the nuclear export of already-activated NFAT.
First, we investigated whether the addition of PP1 alone affected NFAT activity in Wnt-5ahigh cells compared to Wnt-5alow cells, as measured by Western blot analysis. The phosphorylated form of NFAT1 appears to have a molecular mass of approximately 135 kDa, whereas the active, dephosphorylated form, which is sequestered in the nucleus, is about 120 kDa (23, 52, 55). In line with our previous results we found that treatment with PP1 alone caused a slight activation of NFAT1 in both types of cells, an effect that was more pronounced in the Wnt-5ahigh cells (Fig. 5A). Ionomycin activation of NFAT was used as a positive control. Western blotting indicated that the activation reached steady-state levels after approximately 2 to 3 h (data not shown). The degree of activation in the Wnt-5ahigh cells cannot be directly compared to the strong activation observed in the luciferase assays, which measure the accumulated effects of Wnt-5a secretion, Wnt/Ca2+ signaling, and subsequent NFAT activation over a period of 36 h.
|
Neither JNK, GSK-3ß, Pak1, nor Akt is part of the counteracting Wnt-5a signaling. Since serine/threonine kinases phosphorylate NFAT and hence regulate its activation, we sought to investigate potential Wnt-5a/Yes/Cdc42-activated serine/threonine kinases. It has previously been shown that JNK can phosphorylate and thereby inactivate NFAT (4, 15, 34). The RhoGTPase Cdc42 is a signaling molecule that has been shown to be dependent on Src for its activation (62) and also to act upstream of JNK (40). Furthermore, it has been reported that Cdc42 and the serine/threonine kinase JNK may be involved in noncanonical Wnt pathways (41), although existing data are contradictory (63). Nevertheless, we initially hypothesized that JNK is activated by Wnt-5a via Yes and Cdc42 and that it inhibits NFAT activity induced by an agonist-induced Ca2+ signal. First, we investigated the effects of inhibiting JNK on Wnt-5a-induced NFAT activation. The inhibition of JNK did not influence the activation of NFAT in Wnt-5ahigh cells compared to Wnt-5alow cells (Fig. 6A). The results also show that dnRac1 had a much smaller effect on NFAT activation compared to dnCdc42. More importantly, in dnRac1-transfected cells we only found a minute difference in NFAT activation levels between Wnt-5alow and Wnt-5ahigh cells compared to that found in dnCdc42-transfected cells. This indicates that other factors, unrelated to Wnt-5a, can affect NFAT activity via Rac1.
|
It is well established that GSK-3ß is a NFAT kinase, and there is evidence that this protein is stimulated by Cdc42 (11). Therefore, we chose to analyze the status of GSK-3ß activation in cells treated with PP1 or the alternative Src-kinase inhibitor Su6656 (Su6). PP1 (Fig. 6C), but not Su6 (data not shown), caused a slight reduction of GSK-3ß phosphorylation as measured in whole-cell lysates of Wnt-5ahigh and Wnt-5alow cells. More importantly, the PP1-induced decrease in GSK-3ß phosphorylation on Ser-9 cannot explain the PP1-induced activation of NFAT because that would have required inactive GSK-3ß (phosphorylated). Another NFAT kinase is Pak1 (67). Pak1 is activated by both Cdc42 and Rac1 (42). However, neither PP1 (Fig. 6D) nor Su6 (data not shown) affected the phosphorylation-status of Pak1 (Ser 144 in the CRIB domain). We also analyzed the Akt phosphorylation levels in these sets of experiments but found no differences (data not shown).
Small Rho GTPases, such as Cdc42, are all well-known modulators of the actin cytoskeleton (35). It is difficult to imagine that Cdc42 can have a direct effect on NFAT1 serine-phosphorylation and activity. However, it was recently suggested that actin polymerization has a direct impact on the nuclear sequestration of NFAT (51). Therefore, we also studied whether using cytochalasin D, to disrupt filamentous actin, would affect Wnt-5a-induced levels of NFAT activity. We found no effect of cytochalasin D in either the Wnt-5alow or the Wnt-5ahigh cells (Fig. 6E).
CK1
binds to NFAT1 upon Wnt-5a stimulation.
As mentioned above, NFAT proteins have specific serine-rich motifs that are phosphorylated upon inactivation. It has been reported that the different motifs are phosphorylated by distinct kinases and the motif required for nuclear import is regulated primarily through phosphorylation by CK1 (45). The CK-family of proteins is constitutively active serine/threonine kinases that act through complex formation, rather than being activated by phosphorylation (27). Thus, in resting T cells, it was shown that CK1 and NFAT formed a cytoplasmic complex that upon activation dissociated, resulting in the subsequent nuclear localization of NFAT. Interestingly, the involvement of CK proteins has been implicated in both canonical and noncanonical Wnt pathways (16, 18, 19, 27, 59, 60). However, it has not yet been studied whether Wnt proteins can induce complex formation between NFAT and CK1 and thereby inhibit the activation of NFAT. To analyze whether CK1
is a downstream effector of Wnt-5a signaling, we stimulated Wnt-5alow cells with recombinant Wnt-5a and immunoprecipitated NFAT1. As shown in Fig. 7A, we could detect a modest but consistent increase in CK1
binding to NFAT1 upon stimulation with recombinant Wnt-5a. We simultaneously detected a clear activation of NFAT1 as shown by an increase of the faster-migrating band (Fig. 7A, right). We confirmed this association through immunoprecipitations of CK1
and immunoblotting for NFAT1 (Fig. 7B) before and after recombinant Wnt-5a stimulation. Treatment with ionomycin has previously been shown to both activate NFAT but, more importantly, to disrupt the CK1
/NFAT1 binding (45). As shown in Fig. 7B, we demonstrate that upon the addition of recombinant Wnt-5a, the ionomycin-induced disruption of the CK1
/NFAT complex was avoided. In accordance with this, when we inhibited Yes we did not detect the Wnt-5a induced increase in complex formation between CK1
and NFAT1 (Fig. 7B), again indicating that the Wnt-5a-induced Yes/Cdc42 pathway is responsible for the inhibition of NFAT activity. Finally, we examined the ability of recombinant Wnt-5a to counteract ionomycin-induced NFAT activity in Wnt-5alow cells treated with a CK1
inhibitor (Fig. 7C). Indeed, addition of the CK1 inhibitor prevented Wnt-5a from inactivating NFAT1, as measured by nuclear export experiments and using Wnt-5a as a positive control.
|
| DISCUSSION |
|---|
|
|
|---|
Our results indicate that Wnt-5a signaling does regulate NFAT1 activity in mammary cells, as shown by a discrete but statistically significant higher basal activation level of NFAT1 in Wnt-5a-overexpressing HB2 cells. The activation of NFAT1 in breast epithelial cells occurs via a Wnt-5a-induced Ca2+/calmodulin pathway. More importantly, however, we also discovered a novel Wnt-5a-induced Yes/Cdc42/CK1
-dependent mechanism that counteracts both Wnt-5a-induced and Ca2+-induced NFAT1 activation in general. The findings suggest that the Wnt-5a/Ca2+ induced NFAT1 activity is continually antagonized by the Wnt-5a-induced formation of CK1
/NFAT1 complexes in human mammary epithelial cells. In addition, the present observations of simultaneous stimulatory and inhibitory Wnt-5a signals might explain why previous reports concerning Wnt-5a-induced NFAT activation in mammalian cells did not detect significant activation of NFAT by Wnt-5a (61).
In concurrence with some reports concerning Wnt-induced activation of JNK (33, 61), but in contrast to others (17, 41), we did not find a relationship between Wnt-5a-induced activation of Cdc42 and JNK. Likewise, we found no relationships between Cdc42 and other previously suggested proteins that can regulate NFAT activity, including GSK-3ß (3, 11, 43, 45), p38 (14), extracellular signal-regulated kinase (49), Pak1 (67), and Akt (48, 69). In a recent study (69), Akt was found to counteract NFAT activity in breast cancer cells and hence inhibited breast cancer cell invasion, but that study did not address the effects of Wnt-5a. It is well known that the activation of Cdc42 leads to modulation of the actin cytoskeleton. However, such a mechanism is not involved in Cdc42-induced regulation of NFAT, although this has been proposed to occur in other cells (51).
As previously mentioned, recent studies have shown that the canonical and noncanonical Wnt signaling pathways overlap or antagonize each other (63, 66). Wnt-5a belongs to the group of nontransforming Wnts and has been implicated in antagonizing the transforming capacities of canonical Wnt signaling in mammary cells (24, 46). Accordingly, it is reasonable to conclude that the loss of Wnt-5a expression in breast tumors leads to a more malignant phenotype. It does not, however, directly explain why the Wnt-5a negative tumors are more metastatic (9, 25). We have previously shown that loss of Wnt-5a in breast cancer cells leads to inactivation of the DDR1 receptor and thereby reduced adhesion and increased motility (8, 24), thus suggesting one mechanism whereby Wnt-5a could reduce the metastatic potential in breast cancer. In addition, it was recently demonstrated that increased activation of NFAT induced by certain tumor-specific integrins elevates the motility, and thus the invasive potential, of mammary tumor cells (23, 69). In the present study we show that the invasive capacity of human breast epithelial cells is reduced upon treatment with recombinant Wnt-5a. In contrast, in SYF cells lacking all Src-kinase family members the Wnt-5a-induced Ca2+-signal leads to an increased invasive capacity, most likely reflecting an increased NFAT activity. This is supported by the fact that the expression of the negative NFAT regulatory domain VIVIT (2) both reduced the invasive capacity of SYF cells and abrogated the Wnt-5a-induced increase in invasive capacity.
It is intriguing to consider how altered activity of NFAT could relate to the metastatic ability of breast tumor cells, since the subset of genes that are induced by NFAT in tumors remain to be determined. Nevertheless, the present findings suggest that the loss of Wnt-5a, along with the eradication of the antagonizing effect of the protein on NFAT activity, can result in an excessive activation of NFAT by other activating receptors such as tumor-specific integrins, leading to augmented tumor cell motility and invasion. In accordance with this, Wnt-5a counteracted Ca2+-induced activation of NFAT1 by ionomycin. Consequently, the loss of Wnt-5a protein expression and reduced Yes/Cdc42/CK1
signaling may increase the metastatic potential of breast cancer by excessive NFAT activation.
| ACKNOWLEDGMENTS |
|---|
We thank Lena Axelsson for help with invasion assays, J. Taylor-Papadimitriou for providing the HB2 cells, T. Leanderson for the NFAT-pGL2 plasmid, M. Sigvardsson for the TATA-pGL3 plasmid, P. Aspenström for the dnCdc42 and dnRac1 plasmids, B. Williams for the hLRP6 plasmid. We also thank Patricia Ödman for linguistic revision of the manuscript and T. Leanderson and Jill Howlin for scientific discussions and linguistic revision of the manuscript.
| FOOTNOTES |
|---|
J.D. and A.S. contributed equally to this study. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Aramburu, J., M. B. Yaffe, C. Lopez-Rodriguez, L. C. Cantley, P. G. Hogan, and A. Rao. 1999. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285:2129-2133.
3. Beals, C. R., C. M. Sheridan, C. W. Turck, P. Gardner, and G. R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275:1930-1934.
4. Chow, C. W., M. Rincon, J. Cavanagh, M. Dickens, and R. J. Davis. 1997. Nuclear accumulation of NFAT4 opposed by the JNK signal transduction pathway. Science 278:1638-1641.
5. Crabtree, G. R., and E. N. Olson. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl.):S67-S79.[CrossRef][Medline]
6. Davis, R. 2000. Signal transduction by the JNK group of MAP kinases. Cell 103:239-252.[CrossRef][Medline]
7. Dejmek, J., A. Dejmek, A. Safholm, A. Sjolander, and T. Andersson. 2005. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 65:9142-9146.
8. Dejmek, J., K. Dib, M. Jonsson, and T. Andersson. 2003. Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion. Int. J. Cancer 103:344-351.[CrossRef][Medline]
9. Dejmek, J., K. Leandersson, J. Manjer, A. Bjartell, S. O. Emdin, W. F. Vogel, G. Landberg, and T. Andersson. 2005. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin. Cancer Res. 11:520-528.
10. Edlund, S., M. Landstrom, C. Heldin, and P. Aspenstrom. 2002. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol. Biol. Cell 13:902-914.
11. Etienne-Manneville, S., and A. Hall. 2003. Cdc42 regulates GSK-3ß and adenomatous polyposis coli to control cell polarity. Nature 421:753-756.[CrossRef][Medline]
12. Fukuhara, T., K. Shimizu, T. Kawakatsu, T. Fukuyama, Y. Minami, T. Honda, T. Hoshino, T. Yamada, H. Ogita, M. Okada, and Y. Takai. 2004. Activation of Cdc42 by trans interactions of the cell adhesion molecules nectins through c-Src and Cdc42-GEF FRG. J. Cell Biol. 166:393-405.
13. Giles, R. H., J. H. van Es, and H. Clevers. 2003. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653:1-24.[Medline]
14. Gomez del Arco, P., S. Martinez-Martinez, J. L. Maldonado, I. Ortega-Perez, and J. M. Redondo. 2000. A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J. Biol. Chem. 275:13872-13878.
15. Gomez, M., L. Bosc, A. Stevenson, M. Wilkerson, D. Hill-Eubanks, and M. Nelson. 2003. Constitutively elevated nuclear export activity opposes Ca2+-dependent NFATc3 nuclear accumulation in vascular smooth muscle: role of JNK2 and Crm-1. J. Biol. Chem. 278:46847-46853.
16. Ha, N. C., T. Tonozuka, J. L. Stamos, H. J. Choi, and W. I. Weis. 2004. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol. Cell 15:511-521.[CrossRef][Medline]
17. Habas, R., I. B. Dawid, and X. He. 2003. Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev. 17:295-309.
18. Hagen, T., and A. Vidal-Puig. 2002. Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45. Biochem. Biophys. Res. Commun. 294:324-328.[CrossRef][Medline]
19. Hammerlein, A., J. Weiske, and O. Huber. 2005. A second protein kinase CK1-mediated step negatively regulates Wnt signalling by disrupting the lymphocyte enhancer factor-1/ß-catenin complex. Cell Mol. Life Sci. 62:606-618.[CrossRef][Medline]
20. Hatsell, S., T. Rowlands, M. Hiremath, and P. Cowin. 2003. Beta-catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 8:145-158.[CrossRef][Medline]
21. He, X., J. Saint-Jeannet, Y. Wang, J. Nathans, I. Dawid, and H. Varmus. 1997. A member of the Frizzled protein family mediating axis induction by Wnt-5A. Science 275:1652-1654.
22. Hoey, T., Y. L. Sun, K. Williamson, and X. Xu. 1995. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 2:461-472.[CrossRef][Medline]
23. Jauliac, S., C. Lopez-Rodriguez, L. Shaw, L. Brown, A. Rao, and A. Toker. 2002. The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat. Cell Biol. 4:540-544.[CrossRef][Medline]
24. Jonsson, M., and T. Andersson. 2001. Repression of Wnt-5a impairs DDR1 phosphorylation and modifies adhesion and migration of mammary cells. J. Cell Sci. 114:2043-2053.
25. Jonsson, M., J. Dejmek, P. Bendahl, and T. Andersson. 2002. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res. 62:409-416.
26. Klinghoffer, R. A., C. Sachsenmaier, J. A. Cooper, and P. Soriano. 1999. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J. 18:2459-2471.[CrossRef][Medline]
27. Knippschild, U., A. Gocht, S. Wolff, N. Huber, J. Lohler, and M. Stoter. 2005. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 17:675-689.[CrossRef][Medline]
28. Kohn, A. D., and R. T. Moon. 2005. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 38:439-446.[CrossRef][Medline]
29. Kremenevskaja, N., R. von Wasielewski, A. S. Rao, C. Schofl, T. Andersson, and G. Brabant. 2005. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24:2144-2154.[CrossRef][Medline]
30. Kuhl, M., K. Geis, L. C. Sheldahl, T. Pukrop, R. T. Moon, and D. Wedlich. 2001. Antagonistic regulation of convergent extension movements in Xenopus by Wnt/ß-catenin and Wnt/Ca2+ signaling. Mech. Dev. 106:61-76.[CrossRef][Medline]
31. Kuhl, M., L. Sheldahl, M. Park, J. Miller, and R. Moon. 2000. The Wnt/Ca2+ pathway: a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 16:279-283.[CrossRef][Medline]
32. Kuhl, M., L. C. Sheldahl, C. C. Malbon, and R. T. Moon. 2000. Ca2+/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus. J. Biol. Chem. 275:12701-12711.
33. Li, L., H. Yuan, W. Xie, J. Mao, A. M. Caruso, A. McMahon, D. J. Sussman, and D. Wu. 1999. Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun N-terminal kinase in mammalian cells. J. Biol. Chem. 274:129-134.
34. Liang, Q., O. Bueno, B. Wilkins, C. Kuan, Y. Xia, and J. Molkentin. 2003. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin-NFAT signaling. EMBO J. 22:5079-5089.[CrossRef][Medline]
35. Lozano, E., M. Betson, and V. M. Braga. 2003. Tumor progression: small GTPases and loss of cell-cell adhesion. Bioessays 25:452-463.
36. Lustig, B., and J. Behrens. 2003. The Wnt signaling pathway and its role in tumor development. J. Cancer Res. Clin. Oncol. 129:199-221.[Medline]
37. Mao, J., J. Wang, B. Liu, W. Pan, G. r. Farr, C. Flynn, H. Yuan, S. Takada, D. Kimelman, L. Li, and D. Wu. 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7:801-809.[CrossRef][Medline]
38. Mikels, A. J., and R. Nusse. 2006. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 4:e115.[CrossRef][Medline]
39. Miller, J. 2002. The Wnts. Genome Biol. 3:3001.13001.15. [Online.]
40. Minden, A., A. Lin, F. Claret, A. Abo, and M. Karin. 1995. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81:1147-1157.[CrossRef][Medline]
41. Moriguchi, T., K. Kawachi, S. Kamakura, N. Masuyama, H. Yamanaka, K. Matsumoto, A. Kikuchi, and E. Nishida. 1999. Distinct domains of mouse dishevelled are responsible for the c-Jun N-terminal kinase/stress-activated protein kinase activation and the axis formation in vertebrates. J. Biol. Chem. 274:30957-30962.
42. Morreale, A., M. Venkatesan, H. R. Mott, D. Owen, D. Nietlispach, P. N. Lowe, and E. D. Laue. 2000. Structure of Cdc42 bound to the GTPase binding domain of PAK. Nat. Struct. Biol. 7:384-388.[CrossRef][Medline]
43. Murphy, L., and C. Hughes. 2002. Endothelial cells stimulate T-cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the Wnt/glycogen synthase kinase-3 beta pathway. J. Immunol. 169:3717-3725.
44. Nelson, W. J., and R. Nusse. 2004. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303:1483-1487.
45. Okamura, H., C. Garcia-Rodriguez, H. Martinson, J. Qin, D. M. Virshup, and A. Rao. 2004. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol. Cell. Biol. 24:4184-4195.
46. Olson, D., and D. Gibo. 1998. Antisense wnt-5a mimics wnt-1-mediated C57MG mammary epithelial cell transformation. Exp. Cell Res. 241:134-141.[CrossRef][Medline]
47. Pandur, P., D. Maurus, and M. Kuhl. 2002. Increasingly complex: new players enter the Wnt signaling network. Bioessays 24:881-884.[CrossRef][Medline]
48. Patra, A. K., S. Y. Na, and U. Bommhardt. 2004. Active protein kinase B regulates TCR responsiveness by modulating cytoplasmic-nuclear localization of NFAT and NF-
B proteins. J. Immunol. 172:4812-4820.
49. Porter, C. M., M. A. Havens, and N. A. Clipstone. 2000. Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization. J. Biol. Chem. 275:3543-3551.
50. Rao, A., C. Luo, and P. G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15:707-747.[CrossRef][Medline]
51. Rivas, F. V., J. P. O'Keefe, M. L. Alegre, and T. F. Gajewski. 2004. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol. Cell. Biol. 24:1628-1639.
52. Ruff, V. A., and K. L. Leach. 1995. Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. J. Biol. Chem. 270:22602-22607.
53. Saneyoshi, T., S. Kume, Y. Amasaki, and K. Mikoshiba. 2002. The Wnt/calcium pathway activates NF-AT and promotes ventral cell fate in Xenopus embryos. Nature 417:295-299.[CrossRef][Medline]
54. Schweizer, L., and H. Varmus. 2 May 2003, posting date. Wnt/Wingless signaling through beta-catenin requires the function of both LRP/Arrow and frizzled classes of receptors. BMC Cell Biol. 4:4. [Online.] http://www.biomedcentral.com/1471-2121-4-4.[CrossRef][Medline]
55. Scott, J. E., V. A. Ruff, and K. L. Leach. 1997. Dynamic equilibrium between calcineurin and kinase activities regulates the phosphorylation state and localization of the nuclear factor of activated T cells. Biochem. J. 324(Pt. 2):597-603.[Medline]
56. Seidensticker, M., and J. Behrens. 2000. Biochemical interactions in the wnt pathway. Biochim. Biophys. Acta 1495:168-182.[Medline]
57. Sheldahl, L., D. Slusarski, P. Pandur, J. Miller, M. Kuhl, and R. Moon. 2003. Dishevelled activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. J. Cell Biol. 161:769-777.
58. Smalley, M., and T. Dale. 2001. Wnt signaling and mammary tumorigenesis. J. Mammary Gland Biol. Neoplasia 6:37-52.[CrossRef][Medline]
59. Sobrado, P., A. Jedlicki, V. H. Bustos, C. C. Allende, and J. E. Allende. 2005. Basic region of residues 228-231 of protein kinase CK1
is involved in its interaction with axin: binding to axin does not affect the kinase activity. J. Cell Biochem. 94:217-224.[CrossRef][Medline]
60. Takada, R., H. Hijikata, H. Kondoh, and S. Takada. 2005. Analysis of combinatorial effects of Wnts and Frizzleds on beta-catenin/armadillo stabilization and Dishevelled phosphorylation. Genes Cells 10:919-928.
61. Topol, L., X. Jiang, H. Choi, L. Garrett-Beal, P. Carolan, and Y. Yang. 2003. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 162:899-908.
62. Tu, S., W. Wu, J. Wang, and R. Cerione. 2003. Epidermal growth factor-dependent regulation of Cdc42 is mediated by the Src tyrosine kinase. J. Biol. Chem. 278:49293-49300.
63. Veeman, M., J. Axelrod, and R. Moon. 2003. A second canon: functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell 5:367-377.[CrossRef][Medline]
64. Versteeg, H. H., I. Hoedemaeker, S. H. Diks, J. C. Stam, M. Spaargaren, P. M. van Bergen En Henegouwen, S. J. van Deventer, and M. P. Peppelenbosch. 2000. Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac. J. Biol. Chem. 275:28750-28756.
65. Weeraratna, A., Y. Jiang, G. Hostetter, K. Rosenblatt, P. Duray, M. Bittner, and J. Trent. 2002. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288.[CrossRef][Medline]
66. Weidinger, G., and R. T. Moon. 2003. When Wnts antagonize Wnts. J. Cell Biol. 162:753-755.
67. Yablonski, D., L. P. Kane, D. Qian, and A. Weiss. 1998. A Nck-Pak1 signaling module is required for T-cell receptor-mediated activation of NFAT, but not of JNK. EMBO J. 17:5647-5